金吾财讯 | 葛兰素史克（GSK）已与Chimagen Biosciences达成协议，将以高达7.5亿美元的交易总额，收购后者一款用于治疗多发性骨髓瘤的三特异性T细胞衔接器（TCE）项目的全球独家权益。根据协议，GSK将向Chimagen支付一笔首付款，并根据后续研发与商业化进展支付相应的里程碑付款。该候选药物能够同时靶向T细胞及两种肿瘤相关抗原，目前预计将于2027年正式进入I期临床试验阶段。此前，双方已就另一款处于I期临床、针对CD19/CD20的双重TCE药物CMG1A46达成合作，本次交易标志着GSK在多发性骨髓瘤及血液瘤产品线上的进一步深化布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.